Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol/AZ Saxagliptin Safety Review: All Signs Point to Positive Committee Outcome

This article was originally published in The Pink Sheet Daily

Executive Summary

Upcoming FDA advisory committee review of DPP4 inhibitor poses first test of new diabetes cardiovascular safety guidelines. Bristol and AstraZeneca won’t be the only companies watching carefully.

You may also be interested in...



Bristol/AZ Saxagliptin Clears Cardiovascular Safety Hurdle; Approval Timing Still Uncertain

Bristol and FDA need to agree on post-marketing cardiovascular outcomes trial for antidiabetic. Agency mum on efficacy and other safety issues.

Bristol/AZ Saxagliptin Clears Cardiovascular Safety Hurdle; Approval Timing Still Uncertain

Bristol and FDA need to agree on post-marketing cardiovascular outcomes trial for antidiabetic. Agency mum on efficacy and other safety issues.

Novo Nordisk’s Liraglutide Adds Thyroid Cancer Risk To The Diabetes Safety Gauntlet

In addition to weighing prior data against new cardiovascular outcomes standards, FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will assess April 2 whether a cancer risk in rodents translates to humans.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069205

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel